206551-41-9

Basic information

• Product Name: 3-Bromo-2-fluorobenzoic acid methyl ester
• Synonyms: 3-Bromo-2-fluorobenzoic acid methyl ester;methyl 2-fluoro-3-bromobenzoate
• CAS NO: 206551-41-9
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.04
• Product Categories: Aromatic Esters
• Mol File: 206551-41-9.mol

Chemical Properties

• Melting Point: 35-37℃
• Boiling Point: 255℃
• Flash Point: 108℃
• Appearance: White to cream/Fused Solid
• Density: 1.577
• Vapor Pressure: 0.016mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• CAS DataBase Reference: 3-Bromo-2-fluorobenzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-2-fluorobenzoic acid methyl ester(206551-41-9)
• EPA Substance Registry System: 3-Bromo-2-fluorobenzoic acid methyl ester(206551-41-9)

Safety Data

• Hazardous Substances Data: 206551-41-9(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

InChI:InChI=1/C8H6BrFO2/c1-12-8(11)5-3-2-4-6(9)7(5)10/h2-4H,1H3

Upstream product

• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 1007-16-5 3-bromo-4-fluorobenzoic acid 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 77771-03-0 3-bromo-4-fluoro-benzyl alcohol 
• 1042055-86-6 methyl 3-((tert-butoxycarbonyl)amino)-2-fluorobenzoate 
• 939024-44-9 2-fluoro-3-(pyridine-2-yl)benzoic acid trifluoroacetate 
• 1389287-37-9 7-(4-aminophenyl)-1H-indazol-3(2H)-one 
• 1389287-38-0 C₂₁H₁₅F₃N₄O₂ 
• 1195764-77-2 2,6-Difluoro-N-{2-fluoro-3-[2-(1-methylethyl)-5-(2-{[2-(methylsulfonyl)ethyl]amino}-4-pyrimidinyl)-1,3-thiazol-4-yl]phenyl}benzenesulfonamide 
• 1195768-22-9 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1-methylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1195765-45-7 dabrafenib 
• 1195768-23-0 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1 ,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1195768-20-7 N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide 
• 1195768-19-4 3-(2,6-difluorobenzenesulfonamido)-2-fluorobenzoic acid methyl ester 
• 1307272-00-9 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(4-methyltetrahydro-2H-pyran-4-yl)-1,3-thiazol-4-yl]-2-fluorophenyl}-1-propanesulfonamide 
• 1307271-99-3 {3-[5-(2-chloro-4-pyrimidinyl)-2-(4-methyltetrahydro-2H-pyran-4-yl)-1,3-thiazol-4-yl]-2-fluorophenyl}amine 
• 1307271-98-2 2-propen-1-yl {3-[5-(2-chloro-4-pyrimidinyl)-2-(4-methyltetrahydro-2H-pyran-4-yl)-1,3-thiazol-4-yl]-2-fluorophenyl}carbamate 

Relevant articles and documents

Enantioselective Total Synthesis of Beraprost Using Organocatalyst

A convergent and enantioselective total synthesis of the most active isomer of beraprost was achieved in 17 pots. A unique tricyclic core in beraprost was synthesized efficiently by utilizing the asymmetric organocatalyst-mediated formal [3 + 2] cycloaddi

Glucosylceramide synthase inhibitors

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.

Discovery of dabrafenib: A selective inhibitor of Raf Kinases with antitumor activity against B-Raf-driven tumors

Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-RafV600E mutated enzyme has been observed in a number of human tumors, including melanomas. Herein we report the discovery and biological evaluation of GSK2118436, a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-RafV600E human melanoma. GSK2118436 was identified as a development candidate, and early clinical results have shown significant activity in patients with B-Raf mutant melanoma.

Contribution of indazolinone tautomers to kinase activity

The design and synthesis of indazolinone containing kinase inhibitors are reported. Regioisomers that showed profound potency variation in previously-reported isoindolinone and aminoindazole systems were surprisingly found to have similar potencies in the case of the indazolinone chemical series. An interpretation using differential hinge hydrogen bonding and tautomeric equilibrium of indazolinone ring system is supported by quantum mechanics calculations. The equipotent inhibition of a representative kinase (KDR) by regioisomeric indazolinones 4 and 5 is clear evidence that in case of the indazolinone hinge, both tautomers are equally favored, and should be considered in design of inhibitors.

TRICYCLIC INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein X, Y, Z, R3 and R4 are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents

Benzene Sulfonamide Thiazole and Oxazole Compounds

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I) wherein R1, W, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula (I), methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula (I), or compositions including them, to a subject. The invention also comprises further embodiments of Formulas (II) and (III), intermediates and processes useful for the preparation of compounds of the invention.

Cyclocarbamate derivatives as progesterone receptor modulators

This invention provides compounds of Formula (I): wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alkynyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl, alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1 to C3 alky, C1 to C3 alkoxy, C1 to C3 aminoalkyl, CORF, or NRGCORF; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.